Gene delivery systems for treatment of heart failure
AssigneeIcahn School of Medicine at Mount Sinai
InventorsLior ZANGI, Ajit MAGADUM
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to compositions and methods of use thereof for treating heart failure encompassing administering a composition of modified mRNA (modRNA) encoding for type 2 phosphatidylinositol-5-phosphate 4-kinase gamma (pip4k2c) to heart tissue of a subject in need thereof.
Claims23
A method of treating heart failure, the method comprising administering a modified mRNA (modRNA) encoding for type 2 phosphatidylinositol-5-phosphate 4-kinase gamma (pip4k2c) to heart tissue of a subject in need thereof.
A gene delivery system for treatment of heart failure comprising a modified mRNA (modRNA) encoding for type 2 phosphatidylinositol-5-phosphate 4-kinase gamma (pip4k2c).
A method of treating heart failure, the method comprising:
- a) preparing a modified mRNA (modRNA) encoding for type 2 phosphatidylinositol-5-phosphate 4-kinase gamma (pip4k2c), wherein the prepared modRNA does not elicit an immune response compared to exogenous RNA after local administration;
- and,
- b) locally administering the modRNA encoding for pip4k2c to heart tissue of a subject in need thereof, wherein the gene expression of pip4k2c increases after at least one administration.
Dependencies are inferred from the claim text.